|
Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009
CNNMoney.com (press release) This increase primarily reflects on-going expenditures supporting Strativa sales and marketing, driven primarily by an increase in the field force and other … |
Comments on this entry are closed.